Mutation status of the KMT2 family associated with immune checkpoint inhibitors (ICIs) therapy and implicating diverse tumor microenvironments

Mounting evidence suggests a strong association between tumor immunity and epigenetic regulation. The histone-lysine N-methyltransferase 2 (KMT2) family plays a crucial role in the methylation of histone H3 at lysine 4. By influencing chromatin structure and DNA accessibility, this modification serv...

Full description

Saved in:
Bibliographic Details
Published in:Molecular cancer 2024-01, Vol.23 (1), p.15-15, Article 15
Main Authors: Wang, Dong-Xu, Long, Jun-Yu, Li, Rui-Zhe, Zhang, Dao-Lin, Liu, Hui, Liu, Jingru, Tian, Jin-Cheng, Li, Han, Liu, Jie, Zhao, Hai-Tao, Li, Tao
Format: Article
Language:English
Subjects:
Cancer
Chromatin
Clinical outcomes
Colorectal cancer
Correspondence
Cytotoxicity
Development and progression
DNA methylation
DNA structure
Epigenesis, Genetic
Epigenetic inheritance
Epigenetics
Gene mutations
Genes
Genetic aspects
Genomes
Genomics
Histone H3
Histone methyltransferase
Histone-lysine N-methyltransferase
Humans
ICI therapy
Immune checkpoint inhibitors
Immune Checkpoint Inhibitors - therapeutic use
Immunogenicity
Immunological tolerance
Immunotherapy
KMT2 gene family
Lysine
Medical prognosis
Metastases
Methylation
Methyltransferase
Methyltransferases
Mutation
N-Methyltransferase
Neoplasms - drug therapy
Neoplasms - genetics
Oncology, Experimental
Pan-cancer analysis
Phenotypes
Regression analysis
Survival analysis
Tumor Microenvironment
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Mounting evidence suggests a strong association between tumor immunity and epigenetic regulation. The histone-lysine N-methyltransferase 2 (KMT2) family plays a crucial role in the methylation of histone H3 at lysine 4. By influencing chromatin structure and DNA accessibility, this modification serves as a key regulator of tumor progression and immune tolerance across various tumors. These findings highlight the potential significance of the KMT2 family in determining response to immune checkpoint inhibitor (ICI) therapy, which warrants further exploration. In this study, we integrated four ICI-treated cohorts (n = 2069) across 10 cancer types and The Cancer Genome Atlas pan-cancer cohort and conducted a comprehensive clinical and bioinformatic analysis. Our study indicated that patients with KMT2 family gene mutations benefited more from ICI therapy in terms of overall survival (P 
ISSN:1476-4598
1476-4598
DOI:10.1186/s12943-023-01930-8